Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs iShares MSCI South Korea ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.75 (market cap $2.64B), while iShares MSCI South Korea ETF trades at $174.61. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | EWY | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $24.19 | $219.20 |
52-Week Low | $7.82 | $71.22 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EWY, the iShares MSCI South Korea ETF, trades at $174.49, up 6.97% in 24 hours, with a neutral technical signal overall. Recent news highlights South Korea's semiconductor sector volatility and government support initiatives, including a $3.52 billion fund for chip materials. The ETF's performance is tied to heavyweights like Samsung and SK Hynix, which have faced sharp declines amid AI-driven market swings.
Outlook remains cautious due to sector concentration risks and foreign capital outflows, but long-term potential exists if semiconductor demand stabilizes. Investors face volatility from leveraged ETF speculation curbs and global tech sentiment shifts, requiring careful risk assessment amid mixed analyst views.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
